402 related articles for article (PubMed ID: 21362517)
1. Positron emission tomography imaging of cancer biology: current status and future prospects.
Chen K; Chen X
Semin Oncol; 2011 Feb; 38(1):70-86. PubMed ID: 21362517
[TBL] [Abstract][Full Text] [Related]
2. Development of PET probes for cancer imaging.
Huang R; Wang M; Zhu Y; Conti PS; Chen K
Curr Top Med Chem; 2015; 15(8):795-819. PubMed ID: 25732787
[TBL] [Abstract][Full Text] [Related]
3. Current molecular imaging positron emitting radiotracers in oncology.
Zhu A; Shim H
Nucl Med Mol Imaging; 2011 Mar; 45(1):1-14. PubMed ID: 24899972
[TBL] [Abstract][Full Text] [Related]
4. Target-specific delivery of peptide-based probes for PET imaging.
Chen K; Conti PS
Adv Drug Deliv Rev; 2010 Aug; 62(11):1005-22. PubMed ID: 20851156
[TBL] [Abstract][Full Text] [Related]
5. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
6. Molecular imaging of cancer with copper-64 radiopharmaceuticals and positron emission tomography (PET).
Shokeen M; Anderson CJ
Acc Chem Res; 2009 Jul; 42(7):832-41. PubMed ID: 19530674
[TBL] [Abstract][Full Text] [Related]
7. Present role and future prospects of positron emission tomography in clinical oncology.
Oriuchi N; Higuchi T; Ishikita T; Miyakubo M; Hanaoka H; Iida Y; Endo K
Cancer Sci; 2006 Dec; 97(12):1291-7. PubMed ID: 17052261
[TBL] [Abstract][Full Text] [Related]
8. New frontiers in the design and synthesis of imaging probes for PET oncology: current challenges and future directions.
Smith G; Carroll L; Aboagye EO
Mol Imaging Biol; 2012 Dec; 14(6):653-66. PubMed ID: 22948535
[TBL] [Abstract][Full Text] [Related]
9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
10. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
11. Can PET imaging facilitate optimization of cancer therapies?
Kramer-Marek G; Capala J
Curr Pharm Des; 2012; 18(18):2657-69. PubMed ID: 22512443
[TBL] [Abstract][Full Text] [Related]
12. Utility of Molecular Imaging with 2-Deoxy-2-[Fluorine-18] Fluoro-DGlucose Positron Emission Tomography (18F-FDG PET) for Small Cell Lung Cancer (SCLC): A Radiation Oncology Perspective.
Sager O; Dincoglan F; Demiral S; Uysal B; Gamsiz H; Elcim Y; Gundem E; Dirican B; Beyzadeoglu M
Curr Radiopharm; 2019; 12(1):4-10. PubMed ID: 30465520
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.
Pantel AR; Mankoff DA
Cancer Lett; 2017 Feb; 387():25-31. PubMed ID: 27195912
[TBL] [Abstract][Full Text] [Related]
14. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
Høilund-Carlsen PF
Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
[TBL] [Abstract][Full Text] [Related]
15. Pioneering and fundamental achievements on the development of positron emission tomography (PET) in oncology.
Fukuda H; Kubota K; Matsuzawa T
Tohoku J Exp Med; 2013 Jul; 230(3):155-69. PubMed ID: 23883588
[TBL] [Abstract][Full Text] [Related]
16. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
17. Quantitative studies using positron emission tomography (PET) for the diagnosis and therapy planning of oncological patients.
Dimitrakopoulou-Strauss A; Strauss L
Hell J Nucl Med; 2006; 9(1):10-21. PubMed ID: 16617388
[TBL] [Abstract][Full Text] [Related]
18. FDG PET Hybrid Imaging.
Becker J; Schwarzenböck SM; Krause BJ
Recent Results Cancer Res; 2020; 216():625-667. PubMed ID: 32594401
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.
Pantaleo MA; Mishani E; Nanni C; Landuzzi L; Boschi S; Nicoletti G; Dissoki S; Paterini P; Piccaluga PP; Lodi F; Lollini PL; Fanti S; Biasco G
Mol Imaging Biol; 2010 Dec; 12(6):616-25. PubMed ID: 20379787
[TBL] [Abstract][Full Text] [Related]
20. Revisit 18F-fluorodeoxyglucose oncology positron emission tomography: "systems molecular imaging" of glucose metabolism.
Shen B; Huang T; Sun Y; Jin Z; Li XF
Oncotarget; 2017 Jun; 8(26):43536-43542. PubMed ID: 28402949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
